Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder

NCT00236353 is registered in ClinicalTrials.gov with Janssen, LP as lead sponsor.

NCT NCT00236353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00236353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Efficacy and Safety of RISPERDAL Long-acting Microspheres (RISPERDAL CONSTA) Administered Once Monthly in Adults With Schizophrenia or Schizoaffective Disorder
Lead sponsor
Janssen, LP
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2002
Completion date
December 31, 2003
Enrollment
86 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorders, schizophrenia